The company's first quarter adjusted EPS was 71 cents, up 4.4%, and higher than the previous guidance range of 67 cents to 69 cents. GAAP EPS was 61 cents.
First quarter revenue was $4.563 billion, a 5.4% increase over the 2013 first quarter, and up 6.7% on an operational basis.
Revenue growth reflected a 17.5% global reported sales growth from Humira, and double digit growth from other of its main products.
AbbVie confirmed its 2014 adjusted EPS guidance range of $3.00 to $3.10. The GAAP EPPS range is $2.63 to $2.73.
TheStreet Ratings team rates ABBVIE INC as a Hold with a ratings score of C-. TheStreet Ratings Team has this to say about their recommendation:
"We rate ABBVIE INC (ABBV) a HOLD. The primary factors that have impacted our rating are mixed some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and generally higher debt management risk."